Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces financial results for the second quarter ending June 30, 2023, and provides a corporate update: Highlights For Second Quarter and To Date 2023: Therapeutics Highlights: QN-

Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update. Highlights For First Quarter and To Date 2023: Therapeutics Highlights: QN-302 Orphan Drug Designation granted by FDA for the intended indication of pancreatic cancerGood laboratory practice (GLP) toxicology studies initiatedComposition

CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN, Inc.))), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the fourth quarter and fiscal year ended December 31, 2022, and provides an update on the company's therapeutics pipeline and other corporate developments. Highlights For 2022 and to Date: Therapeutics Highlights: QN-302 Secured worldwide rights to G4-selective transcription inhibitors from University College London to develop as cancer therapeuticsEngaged QN

Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic programs and acquisition of majority stake in NanoSynex strengthen Company's diversified product portfolio CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its financial results for the second quarter ended June 30, 2022, and provides an update on its t

Transaction expected to significantly advance commercial readiness of NanoSynex's innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market Company to hold conference call today, June 2, 2022 at 1:00PM ET to discuss latest corporate developments CARLSBAD, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based de

Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million, compared to $3.2 million in the same nine-month period of the previous yearCash equivalents of approximately $12.3 million as of September 30, 2021 CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of adult and pediatric patients with rare cancers, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced its financial resul

Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT. Revenues Increased 30 Percent to $1.9 Million Compared to $1.5 Million in the Same Quarter of the Previous YearOn Track to File an IND in 2H21 for Treating Hospitalized COVID-19 Patients with QN-165Completed the R&D Evaluation and Qualification for QN-247; Expect to Finalize Formulation in 2H21Quarter-End Cash and Cash Equivalents Approximately $21.9 Million; Provides Sufficient Runway to Accomplish Key Inflection Points CARLSBAD, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral disea

8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

NT 10-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

EFFECT - Qualigen Therapeutics, Inc. (0001460702) (Filer)

S-1 - Qualigen Therapeutics, Inc. (0001460702) (Filer)

D - Qualigen Therapeutics, Inc. (0001460702) (Filer)

8-K/A - Qualigen Therapeutics, Inc. (0001460702) (Filer)

8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

10-Q - Qualigen Therapeutics, Inc. (0001460702) (Filer)

CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. On September 25, 2024, the board of directors appointed Campbell Becher as President of the

CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company's newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company's diagnostics division. "Shishir's consistent leadership as chief operating officer has been an essential part of our strategy to date. With the return of the sales and marketing of FastPack® last month, our diagnostics business is an essential asset to t

New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, today announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer. Dr. Arshad brings more than 20 years of biotech and pharmaceutical experience to Qualigen Therapeutics during a dynamic time of growth and implementation of long-range strategy. "We are delighted to welcome Tariq to Qualigen as our Chief Medical Off

CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the "Listing Rule") as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024 (the "2024 Form 10-K"), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the "Form 12b-25") filed with the Securities and Exchange Co

CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC:MRZM). Qualigen and Marizyme have entered an MOU dated March 28, 2025. This is the logical next step in acquiring Marizyme, following on our co-marketing agreement established in 2024. Upon completion of full due diligence, we will proceed with the final structure and deal terms which will be subject to shareholder approval following the filing of an S4. There can be no assurance that any transaction will be completed or that definitive agreements will be executed. Marizym

Market size expected to reach $4.7 billion in 2027 CARLSBAD, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company")announced today they will be the first investors participating in the 2025 bridge round of funding for NanoSynex. NanoSynex will be raising up to $500,000. "We are very excited to participate and be the first investors to commit in this round of funding for NanoSynex. The technology they are developing will help the world of Antimicrobial Susceptibility Testing (AST) by reducing the time required for tests in half, offering more robust diagnostics, which will lead to better use and not over use of the wrong antibiotics for patient

Carlsbad, CA, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics (NASDAQ:QLGN) (the "Company" or "Qualigen") today announced that the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement (the "Bid Price Requirement") set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq's stockholders' equity requirement ("Equity Requirement") set forth in Nasdaq Listing Rule 5550(b)(1). The Hearing Panel has determined to impose a Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A) for a period of one year from December 2, 2024, to make sure that the Company demonstrates long-

New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations. The aggregate gross proceeds to the Company of the offering were approximately $5.1 million, before deducting placement agent fees and

Carlsbad, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), Qualigen Therapeutics, Inc., is a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations, announced today that it has entered into definitive securities purchase agreements with several institutional and accredited investors (the "Investors") for the sale of its preferred shares. Qualigen sold an aggregate of 4,500 shares of its Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for aggregate gross proceeds of US$4.5 million, before deducting placement agent fees

CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "QLGN." The new CUSIP number for the common stock will be 74754R 301. The Reverse Stock Split is intended to increase the bid price of the common stock to enable the Company to regai

CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. On September 25, 2024, the board of directors appointed Campbell Becher as President of the

CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the Nasdaq Hearings Panel ("Panel") has granted an extension for the continued listing of the Company, subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 19, 2024. The Company is diligently working to fulfill the requirements set forth by the Panel to ensure the Company's continued listing on Nasdaq. About Qualigen Therapeutics, Inc. For more information about Qualigen Therapeutics, Inc., pleas

New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the "Offering") of (i) 14,724,058 shares of common stock priced at $0.130 per share, with pre-funded warrants exercisable for 11,972,754 shares with respect to the registered direct offering for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company"), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Under the terms of the securities purchase agreement, the Company has ag

3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

SC 13G/A - Qualigen Therapeutics, Inc. (0001460702) (Subject)

SC 13G - Qualigen Therapeutics, Inc. (0001460702) (Subject)